UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 90

Sortiert nach

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

The New England journal of medicine, 2015-01, Vol.372 (5), p.426-435

2015

Volltextzugriff (PDF)

Age Is Just a Number: Considerations for Older Adults in Cancer Clinical Trials

JNCI : Journal of the National Cancer Institute, 2021-11, Vol.113 (11), p.1460-1464

2021

Volltextzugriff (PDF)

Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration

Magnetic resonance in medicine, 2014-06, Vol.71 (6), p.2215-2223

2014

Volltextzugriff (PDF)

Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia

Oncology and therapy, 2024-03, Vol.12 (1), p.115-129

2024

Volltextzugriff (PDF)

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

Haematologica (Roma), 2012-09, Vol.97 (9), p.1364-1371

2012

Volltextzugriff (PDF)

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

Haematologica (Roma), 2010-04, Vol.95 (4), p.557-566

2010

Volltextzugriff (PDF)

Addressing racial/ethnic disparities in cancer clinical trials: Everyone has a role to play

Cancer, 2021-09, Vol.127 (18), p.3282-3289

2021

Volltextzugriff (PDF)

Deferasirox for up to 3 years leads to continued improvement of myocardial T2 in patients with β-thalassemia major

Haematologica (Roma), 2012-06, Vol.97 (6), p.842-848

2012

Volltextzugriff (PDF)

Patients at the Heart of the Scientific Dialogue: An Industry Perspective

Oncology and therapy, 2023-03, Vol.11 (1), p.15-24

2023

Volltextzugriff (PDF)

Correction: Patients at the Heart of the Scientific Dialogue: An Industry Perspective

Oncology and therapy, 2023-03, Vol.11 (1), p.25-25

2023

Volltextzugriff (PDF)

Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study

Haematologica (Roma), 2013-07, Vol.98 (7), p.1045-1048

2013

Volltextzugriff (PDF)

Reimagining diversity in multiple myeloma clinical trials

Hematological oncology, 2022-10, Vol.40 (4), p.689-694

2022

Volltextzugriff (PDF)

Continued improvement in myocardial T2 over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

Haematologica (Roma), 2011-01, Vol.96 (1), p.48-54

2011

Volltextzugriff (PDF)

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial

Anemia, 2012-01, Vol.2012, p.297641-10

2012

Volltextzugriff (PDF)

Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox

International journal of hematology, 2011-03, Vol.93 (3), p.319-328

2011

Volltextzugriff (PDF)

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Haematologica (Roma), 2016-07, Vol.101 (7), p.821

2016

Volltextzugriff (PDF)

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Blood, 2015-06, Vol.125 (25), p.3868-3877

2015

Volltextzugriff (PDF)

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Blood, 2012-08, Vol.120 (5), p.970-977

2012

Volltextzugriff (PDF)

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF)

British journal of haematology, 2017-01, Vol.176 (1), p.76-85

2017

Volltextzugriff (PDF)

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)

Blood, 2014-03, Vol.123 (10), p.1447-1454

2014

Volltextzugriff (PDF)

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion‐dependent anaemia and iron overload

British journal of haematology, 2009-12, Vol.147 (5), p.752-759

2009

Volltextzugriff (PDF)

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Blood, 2010-03, Vol.115 (12), p.2364-2371

2010

Volltextzugriff (PDF)

Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study

European journal of haematology, 2015-09, Vol.95 (3), p.244-253

2015

Volltextzugriff (PDF)

Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia

British journal of haematology, 2015-01, Vol.168 (2), p.284-290

2015

Volltextzugriff (PDF)

Deferasirox effect on renal haemodynamic parameters in patients with transfusion‐dependent β thalassaemia

British journal of haematology, 2015-03, Vol.168 (6), p.882-890

2015

Volltextzugriff (PDF)

1 – 25 von 90

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(89)

Publikationsform

Artikel
(90)

Sprache

Englisch
(90)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(41)
Science & Technology
(41)
Humans
(38)
Hematology
(36)
Female
(32)
Male
(32)
Adult
(29)
Adolescent
(25)
Child
(21)
Deferasirox
(20)
Iron Overload - Drug Therapy
(20)
Iron Chelating Agents - Therapeutic Use
(19)
Young Adult
(19)
Benzoates - Therapeutic Use
(18)
Middle Aged
(18)
Triazoles - Therapeutic Use
(18)
Ferritins - Blood
(17)
Prospective Studies
(15)
Iron Chelating Agents - Administration & Dosage
(14)
Treatment Outcome
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Age Is Just a Number: Considerations for Older Adults in Cancer Clinical Trials

Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration

Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

Addressing racial/ethnic disparities in cancer clinical trials: Everyone has a role to play

Deferasirox for up to 3 years leads to continued improvement of myocardial T2 in patients with β-thalassemia major

Patients at the Heart of the Scientific Dialogue: An Industry Perspective

Correction: Patients at the Heart of the Scientific Dialogue: An Industry Perspective

Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study

Reimagining diversity in multiple myeloma clinical trials

Continued improvement in myocardial T2 over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial

Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF)

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion‐dependent anaemia and iron overload

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study

Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia

Deferasirox effect on renal haemodynamic parameters in patients with transfusion‐dependent β thalassaemia

Suchergebnisse filtern